Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)

NCT01244828 | Completed Phase 3 Results

• 3 other identifiers: P06238132325MK-8274-042
• Study Type: interventional
• Target: 157
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a multi-site, open-label fixed-flexible dose long-term study of asenapine in participants with schizophrenia. Participants in this study consist of schizophrenia with residual subtype or receiving high dose/multiple antipsychotic drugs, treatment refractory, or elderly participants with schizophrenia. The treatment period is up to 52 weeks.

Conditions

Schizophrenia

Outcome Measures

Primary Outcomes (9)

• Change From Baseline in Weight at Week 52

  For each participant, change from baseline in weight was calculated as the Week 52 value minus the baseline value.

  Baseline and Week 52

• Change From Baseline in BMI at Week 52

  For each participant, change from baseline in BMI was calculated as the Week 52 value minus the baseline value.

  Baseline and Week 52

• Number of Participants With Extrapyramidal Symptoms

  This measure reports the overall number of participants with any of a group of adverse events that were defined to represent extrapyramidal symptoms. The number of participants with each of the individual adverse events within this definition is also presented, for terms that occurred in at least one participant. For this measure, all adverse event terms within the Medical Dictionary for Regulatory Activities (MedDRA) Standardized MedDRA Query (SMQ) for "extrapyramidal syndrome" were treated as extrapyramidal symptoms.

  Up to 30 days after last dose of study drug (Up to approximately 56 weeks)

• Change From Baseline in HbA1c at Week 52

  Blood samples for determination of HbA1c were obtained at baseline and during the study. For each participant, change from baseline in HbA1c at Week 52 was calculated as the Week 52 value minus the baseline value.

  Baseline and Week 52

• Change From Baseline in Fasting Glucose at Week 52

  Blood samples for determination of fasting glucose level were obtained at baseline and during the study. For each participant, change from baseline in fasting glucose at Week 52 was calculated as the Week 52 level minus the baseline level.

  Baseline and Week 52

• Change From Baseline in Insulin at Week 52

  Blood samples for determination of insulin level were obtained at baseline and during the study. For each participant, change from baseline in insulin at Week 52 was calculated as the Week 52 level minus the baseline level.

  Baseline and Week 52

• Change From Baseline in Prolactin at Week 52

  Blood samples for determination of prolactin level were obtained at baseline and during the study. For each participant, change from baseline in prolactin at Week 52 was calculated as the Week 52 level minus the baseline level.

  Baseline and Week 52

• Change From Baseline in PANSS Total Score at Week 52

  The PANSS is a 30-item clinician-rated instrument for assessing the symptoms of schizophrenia. It consists of 3 subscales: positive subscale (7 items), negative subscale (7 items), and general psychopathology subscale (16 items). Positive symptoms refer to an excess or distortion of normal mental status (e.g., delusions). Negative symptoms represent a diminution or loss of normal functions (e.g., emotional withdrawal). For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. The PANSS total score for each participant was calculated as the sum of the rating assigned to each of the 30 PANSS items, and ranged from 30 to 210 with a higher score indicating greater severity of symptoms. The reported measure is the change from baseline at Week 52 (calculated for a participant as Week 52 value minus baseline value); improvement in symptoms is represented by negative values.

  Baseline and Week 52

• Change From Baseline in PANSS Total Score at Final Assessment

  The PANSS is a 30-item clinician-rated instrument for assessing the symptoms of schizophrenia. It consists of 3 subscales: positive subscale (7 items), negative subscale (7 items), and general psychopathology subscale (16 items). Positive symptoms refer to an excess or distortion of normal mental status (e.g., delusions). Negative symptoms represent a diminution or loss of normal functions (e.g., emotional withdrawal). For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. The PANSS total score for each participant was calculated as the sum of the rating assigned to each of the 30 PANSS items, and ranged from 30 to 210 with a higher score indicating greater severity of symptoms. The reported measure is the change from baseline at the final assessment for a participant (calculated for a participant as final assessment value minus baseline value); improvement in symptoms is represented by negative values.

  Baseline up to Week 52

Study Arms (1)

Asenapine

EXPERIMENTAL

Asenapine 5 mg twice daily (BID) for the first week of treatment, then either 5 mg or 10 mg BID.

Drug: Asenapine

Interventions

Asenapine DRUG

5 mg or 10 mg fast-dissolving sublingual tablets BID for up to 52 weeks

Asenapine

Eligibility Criteria

• Age: 20 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Minimum age of 20 years
• Participants who meet at least one of the following:
• current diagnosis of schizophrenia of residual subtype
• received treatment with 3 or more antipsychotic drugs
• treatment-refractory participants with schizophrenia
• years old and over with positive schizophrenia symptoms with score of 3 (mild) or more in 1 or more items in the positive subscale of the Positive and Negative Syndrome Scale (PANSS) at the baseline
• Participants who have a Clinical Global Impressions-Severity (CGI-S) score of at least 4 (moderately ill) at the baseline

You may not qualify if:

• Uncontrolled, unstable clinically significant medical condition
• Clinically significant abnormal laboratory, vital sign, physical examination, or electrocardiogram (ECG) findings at Screening
• Positive pregnancy test at Screening, or the intention to become pregnant during the course of the study
• Seizure disorder beyond childhood (12 years old or younger)
• History of neuroleptic malignant syndrome
• Allergy or sensitivity to drugs such as psychotropics and antipsychotics
• Known history of or currently treated for narrow angle glaucoma
• Parkinson's disease
• Diagnosis of schizoaffective disorder; schizophreniform disorder
• Concurrent psychiatric disorder other than schizophrenia coded on Axis I; a primary diagnosis other than schizophrenia
• Diagnosis of borderline personality disorder
• Diagnosis of mental retardation or organic brain disorder
• Current (past 6 months) substance abuse or dependence according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria (excluding nicotine)
• Positive drug/alcohol tests at the Screening visit
• Imminent risk of self-harm or harm to others, in the Investigator's opinion

Sponsors & Collaborators

• Organon and Co: lead

MeSH Terms

Conditions

Schizophrenia

Interventions

asenapine

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders

Results Point of Contact

• Title: Senior Vice President, Global Clinical Development
• Organization: Merck Sharp & Dohme Corp.

ClinicalTrialsDisclosure@merck.com

1-800-672-6372

Study Officials

• Medical Director

  Merck Sharp & Dohme LLC

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 18, 2010
• First Posted: November 19, 2010
• Study Start: April 5, 2011
• Primary Completion: August 21, 2014
• Study Completion: August 21, 2014
• Last Updated: May 28, 2024
• Results First Posted: August 26, 2015

Record last verified: 2022-02

Data Sharing

• IPD Sharing: Will not share